Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Baxdrostat and Dapagliflozin for Adults with Chronic Kidney Disease and High Blood Pressure

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Featured sites

Sites that work closely with us on this trial

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a combination treatment for people with Chronic Kidney Disease (CKD) and high blood pressure. The study will use two medications: Baxdrostat and Dapagliflozin. Baxdrostat is a new medication being tested, while Dapagliflozin is already used to treat certain conditions. The purpose of the study is to find out if the combination of Baxdrostat and Dapagliflozin is more effective than Dapagliflozin alone in slowing down the progression of CKD.

Participants in the study will be randomly assigned to receive either the combination of Baxdrostat and Dapagliflozin, Dapagliflozin alone, or a placebo. The study will last for up to 26 weeks, during which participants will take the medication in the form of tablets by mouth. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The main focus will be on changes in kidney function, measured by a test called estimated glomerular filtration rate (eGFR), which helps assess how well the kidneys are working.

By participating in this study, researchers hope to gather important information about the safety and effectiveness of the combination treatment for people with CKD and high blood pressure. This could potentially lead to better treatment options in the future for managing these conditions. The study is designed to ensure the safety and well-being of all participants, with regular monitoring and support provided throughout the trial period.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria such as age, kidney function, and blood pressure levels.

    Participants must have chronic kidney disease (CKD) and high blood pressure, with specific measurements for kidney function and blood pressure.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to establish baseline measurements. This includes evaluating kidney function through estimated glomerular filtration rate (eGFR) and urine albumin creatinine ratio (UACR).

    Blood pressure is also measured to ensure it meets the study's requirements.

  3. Step 3

    Medication administration

    Participants are randomly assigned to receive either a combination of baxdrostat and dapagliflozin or dapagliflozin alone.

    Baxdrostat and dapagliflozin are administered orally in tablet form. The dosage and frequency are determined by the study protocol.

  4. Step 4

    Ongoing monitoring

    Regular monitoring is conducted to assess the progression of CKD and the effects of the medication.

    This includes periodic measurements of eGFR, UACR, and blood pressure.

  5. Step 5

    End of treatment evaluation

    At the end of the treatment period, a final evaluation is conducted to measure changes from baseline in eGFR and other health indicators.

    The study aims to determine if the combination of baxdrostat and dapagliflozin is more effective than dapagliflozin alone in slowing CKD progression.

Who can join the trial?

7 criteria

  • Participants of any sex and gender must be **18 years old or older** at the time of signing the informed consent.
  • Participants must have **chronic kidney disease (CKD)** with an **eGFR** (estimated glomerular filtration rate) between **30 and 90 mL/min/1.73 m²** at screening. eGFR is a test that shows how well your kidneys are working.
  • Participants must have a **urine albumin creatinine ratio** greater than **200 mg/g** (22.6 mg/mmol) and less than **5000 mg/g** (565 mg/mmol) at screening. This test measures protein in your urine, which can indicate kidney problems.
  • Participants must have a history of **hypertension (HTN)**, which means high blood pressure, and a **systolic blood pressure (SBP)** of at least **130 mmHg** at screening and at least **120 mmHg** at the randomization visit. SBP is the top number in a blood pressure reading.
  • Participants must be on a stable and maximum tolerated dose of an **ACE inhibitor** or an **ARB** (not both) for at least **4 weeks** before the screening visit. These are types of medications used to treat high blood pressure and kidney problems.
  • Participants must have a **serum potassium** level that meets specific criteria at the screening visit, based on their eGFR:
    • For participants with an eGFR of **45 mL/min/1.73 m² or higher**, potassium must be between **3.5 and 4.8 mmol/L**.
    • For participants with an eGFR less than **45 mL/min/1.73 m²**, potassium must be between **3.5 and 4.5 mmol/L**.

Who cannot join the trial?

10 criteria

  • Patients with severe liver disease cannot participate.
  • Individuals with a history of allergic reactions to the study drugs are excluded.
  • Pregnant or breastfeeding women are not allowed to join the study.
  • People with uncontrolled diabetes, meaning their blood sugar levels are not well-managed, cannot take part.
  • Participants who have had a heart attack or stroke in the past 6 months are excluded.
  • Individuals with a history of drug or alcohol abuse in the past year cannot participate.
  • Patients currently taking certain medications that might interfere with the study drugs are not eligible.
  • Anyone with a serious infection or illness that requires hospitalization is excluded.
  • Individuals with a history of cancer, except for certain types of skin cancer, cannot join the study.
  • Patients with a history of organ transplant are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Baxdrostat

    is a medication being studied to see if it can help slow down the progression of chronic kidney disease (CKD) in people who also have high blood pressure. It is being tested in combination with another medication to see if it works better than the other medication alone.

  • Dapagliflozin

    is a medication that is already used to treat certain conditions, including chronic kidney disease and high blood pressure. In this study, it is being used to see how well it works on its own and in combination with another medication to slow down the progression of chronic kidney disease.

What is already known about the treatment

  • Baxdrostat

    Baxdrostat is administered orally and is currently being studied in clinical trials for its potential benefits in treating chronic kidney disease (CKD) and hypertension. It is not yet widely recognized in medical literature as it is still under investigation. The main therapeutic indication for Baxdrostat is to slow the progression of CKD in patients with high blood pressure. At the molecular level, Baxdrostat works by inhibiting aldosterone synthase, which reduces the production of aldosterone, a hormone that can contribute to kidney damage and high blood pressure. It is classified pharmacologically as an aldosterone synthase inhibitor.

  • Dapagliflozin

    Dapagliflozin is taken orally and is an established medication used to manage chronic kidney disease and high blood pressure. It is well-documented in medical literature and is approved for use in these conditions. The primary therapeutic indication for Dapagliflozin is to improve kidney function and control blood pressure in patients with CKD. Its mechanism of action involves inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which helps to lower blood sugar levels and reduce the workload on the kidneys. Dapagliflozin is classified as an SGLT2 inhibitor.

Investigated diseases

  • Chronic Kidney Disease

    Chronic kidney disease is a long-term condition where the kidneys gradually lose their ability to filter waste and excess fluids from the blood. Over time, this can lead to a buildup of waste products in the body, causing symptoms like fatigue, swelling, and changes in urination. The disease progresses through stages, with each stage indicating a further decline in kidney function. As the condition advances, it can lead to complications such as high blood pressure, anemia, and bone disease. Monitoring kidney function through tests like eGFR is crucial to understanding the progression of the disease. Lifestyle changes and medications can help manage symptoms and slow progression.

  • Hypertension

    Hypertension, commonly known as high blood pressure, is a condition where the force of the blood against the artery walls is consistently too high. This condition often develops over many years and can lead to serious health problems, such as heart disease and stroke, if left unmanaged. Hypertension is often called a "silent killer" because it may not present noticeable symptoms until significant damage has occurred. The progression of hypertension can lead to complications affecting the heart, brain, kidneys, and eyes. Regular monitoring of blood pressure is essential to detect and manage this condition effectively. Lifestyle changes and medications can help control blood pressure levels.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506457-38-00Protocol codeD6972C00003Estimated enrolment2 500 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).